这可能是一个死胡同:在EGFR突变的NSCLC中,免疫检查点抑制剂治疗可能是死胡同
Ken Akao1, Yuko Oya1, Takaya Sato1
1Department of Respiratory Medicine, School of medicine, Fujita Health University, Toyoake 470-1192, Japan.
Exploration of targeted anti-tumor therapy
|September 16, 2024
概括
免疫检查点抑制剂 (ICI) 在EGFR突变非小细胞肺癌 (NSCLC) 中具有有限的疗效. 本综述探讨了ICI在TKI耐药NSCLC中的潜力,重点关注克服治疗挑战.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 分子生物学分子生物学
背景情况:
- 免疫检查点抑制剂 (ICI) 已经彻底改变了癌症治疗,但在EGFR突变非小细胞肺癌 (NSCLC) 中表现出有限的疗效.
- 像PD-L1和TILs这样的传统生物标志物在这个特定的患者群体中不可靠.
- 组合疗法 (例如PD-L1和CTLA-4抑制剂) 由于毒性和疗效问题存在挑战.
研究的目的:
- 对EGFR突变NSCLC的ICI治疗现有证据进行全面审查.
- 总结ICI在患者耐受EGFR-氨酸激酶抑制剂 (TKI) 的潜力.
- 为了探索患者的治疗策略,在 osimertinib 上进展或没有 T790M 突变的患者.
主要方法:
- 对EGFR突变NSCLC的ICI治疗现有文献的系统综述.
- 在EGFR突变的背景下对生物标志物的实用性 (PD-L1,TILs) 的分析.
- 评估组合策略及其疗效和毒性概况.
主要成果:
- 目前的ICI单疗法和组合策略在EGFR突变NSCLC中显示出不充分的疗效.
- 瘤微环境的特异性有助于缺乏对ICI的反应.
- 关于ICI在早期NSCLC与晚期相比的疗效的数据有限.
结论:
- 需要新的治疗策略来提高EGFR突变NSCLC的ICI疗效.
- 需要进一步的研究来确定预测生物标志物和优化治疗方案.
- 探索TCI耐药NSCLC中的ICI潜力需要进一步调查.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
7.9K
08:52Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
4.0K
相关概念视频
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Tumor Immunotherapy
491
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
491
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
